Acrivon Therapeutics, Inc.
ACRV
$1.47
-$0.17-10.37%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.21M | 24.46M | 24.05M | 22.64M | 21.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.20M | 85.30M | 76.30M | 70.38M | 67.10M |
| Operating Income | -89.20M | -85.30M | -76.30M | -70.38M | -67.10M |
| Income Before Tax | -80.56M | -76.98M | -69.00M | -64.12M | -60.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.56 | -76.98 | -69.00 | -64.12 | -60.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.56M | -76.98M | -69.00M | -64.12M | -60.39M |
| EBIT | -89.20M | -85.30M | -76.30M | -70.38M | -67.10M |
| EBITDA | -88.19M | -84.45M | -75.56M | -69.74M | -66.57M |
| EPS Basic | -2.44 | -2.70 | -2.77 | -2.88 | -2.73 |
| Normalized Basic EPS | -1.54 | -1.71 | -1.75 | -1.82 | -1.73 |
| EPS Diluted | -2.44 | -2.70 | -2.77 | -2.88 | -2.73 |
| Normalized Diluted EPS | -1.54 | -1.71 | -1.75 | -1.82 | -1.73 |
| Average Basic Shares Outstanding | 135.07M | 119.16M | 103.14M | 88.98M | 88.31M |
| Average Diluted Shares Outstanding | 135.07M | 119.16M | 103.14M | 88.98M | 88.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
